Condition
Stage 4 NSCLC
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07365319Phase 2Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07597070Phase 2Not Yet RecruitingPrimary
Universal Immunization to Fortify Immunotherapy Efficacy and Response
NCT06262321Phase 2RecruitingPrimary
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Showing all 3 trials